TrialFrontiers in immunology2025

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.

Kwadwo Ansah Koram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.